Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
PacBio (Pacific Biosciences of California, Inc., NASDAQ: PACB) is a life science technology company focused on advanced genetic sequencing, and its news flow reflects developments across genomics research, collaborations, and financial performance. The company regularly issues press releases describing how its HiFi long-read sequencing platforms are being adopted in human health, rare disease research, and other genomics applications.
Recent PacBio news highlights planned collaborations with organizations such as the n-Lorem Foundation and EspeRare to apply long-read whole-genome sequencing in research on individualized antisense oligonucleotide therapies for ultra-rare and nano-rare genetic diseases. Other coverage includes projects where PacBio HiFi sequencing is used as a first-line whole-genome approach in studies of Sudden Unexplained Death in Childhood, and multi-center research through the HiFi Solves Consortium evaluating the clinical research utility of HiFi genomes in complex genomic regions.
Investors and researchers following PACB news will also find updates on technology advances, such as the community-developed CiFi long-read 3C method that integrates chromatin conformation capture with HiFi sequencing, and regulatory milestones achieved through partners like Berry Genomics in China with the Sequel II CNDx system. Financial news includes quarterly and preliminary annual revenue announcements, details on instrument and consumable performance, and commentary on new sequencing chemistries and assay portfolios.
This PACB news page on Stock Titan aggregates these types of announcements so readers can track PacBio’s research collaborations, technology developments, regional partnerships, and earnings-related updates in one place. Users interested in genomic sequencing, long-read technologies, and the business outlook for PacBio can review the latest press releases and historical news items to understand how the company’s platforms are being used and how management describes its progress.
PacBio (NASDAQ: PACB) announced the granting of stock options and restricted stock units (RSUs) totaling 150,000 shares to a newly hired employee under the 2020 Inducement Equity Incentive Plan, effective February 22, 2022. The options have an exercise price of $10.32 per share, matching the closing stock price on the effective date. The vesting schedule includes a one-year cliff and monthly vesting thereafter for the options, while the RSUs will vest annually over four years.
PacBio (NASDAQ: PACB) has appointed Michael Eberle, Ph.D., as Vice President of Computational Biology. Eberle, a seasoned genomics expert with over 20 years of experience, will lead the bioinformatics and data sciences program to enhance PacBio’s genomic analysis capabilities. His leadership, particularly from his previous role at Illumina, is expected to drive innovation and support the growing global customer base. The company remains committed to its mission of advancing genomic research through long- and short-read sequencing technologies.
PacBio has partnered with KK Women’s and Children’s Hospital to enhance the understanding of genetic causes related to neurodevelopmental disorders in children.
This collaboration is part of the BRIDGES program, aiming to improve diagnostic yields beyond the 39% achieved by current short-read sequencing methods. By using PacBio’s HiFi long-read sequencing technology, they hope to address unresolved rare diseases and establish a bioinformatics pipeline for better variant detection.
Leadership from both organizations underscores the potential to improve health outcomes for affected families.
PacBio (NASDAQ: PACB) reported record fourth quarter revenues of $36.0 million, a 33% increase from the previous year. The company expanded the installed base of its Sequel II/IIe systems by 84% to 374. Key advancements include the launch of the HiFiViral SARS-CoV-2 Kit and collaborations with Genomics England and Google. Despite these achievements, PacBio experienced a net loss of $69.3 million for the quarter, a decline from $74.9 million net income in Q4 2020. For fiscal year 2021, revenue rose to $130.5 million, a 65% increase, yet net loss was $181.2 million.
PacBio announced that its executives will present at two upcoming investor conferences: the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 3:00 pm ET, and the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 1:30 pm ET. Both presentations will be accessible via live webcasts at PacBio's investors page, with replays available for 30 days. PacBio, traded on NASDAQ under the symbol PACB, specializes in advanced sequencing technology that enhances genetic research across various scientific fields.
PacBio (NASDAQ: PACB) announced it will hold its quarterly conference call to discuss the fourth quarter and full year 2021 financial results on February 15, 2022, at 4:30 pm ET. This call will be accessible via a live webcast on the Pacific Biosciences website. The company aims to provide insights into its financial performance and future outlook, reflecting its commitment to empowering life scientists through advanced sequencing technologies.
PacBio (NASDAQ: PACB) announced on January 14, 2022, that its Compensation Committee granted non-qualified stock options for 80,000 shares and restricted stock units (RSUs) for 40,000 shares to a new employee. This action is part of the 2020 Inducement Equity Incentive Plan, aimed at attracting talent. The options have an exercise price of $16.58, equal to the stock's closing price on January 10, 2022. Vesting for options and RSUs will occur over four years, aligning employee incentives with long-term company performance.
PacBio has appointed Lara Toerien, Ph.D., as Vice President and General Manager for the Americas region, aiming to enhance its commercial growth strategy. Toerien brings over 25 years of experience, previously serving as Senior Regional Sales Director at Illumina. She will focus on expanding the adoption of PacBio’s long-read sequencing technology across various fields, including infectious diseases and genomics. PacBio’s innovative SMRT Sequencing technology is well-regarded in the scientific community, facilitating comprehensive genetic analysis globally.
PacBio (NASDAQ: PACB) has announced a new collaboration with Berry Genomics to develop a desktop long read sequencing platform for the clinical market in China. Under the agreement, Berry Genomics will purchase at least 50 systems upon meeting product requirements. This partnership aims to expand the accessibility of PacBio's HiFi sequencing technology in Chinese laboratories, boosting offerings in the perinatal and carrier testing market. Building on a successful 2019 agreement, this initiative is expected to enhance the utilization of long read sequencing in clinical settings.
PacBio (NASDAQ: PACB) announces collaboration with Genomics England to explore the effectiveness of HiFi sequencing technology in identifying genetic variants in unexplained rare disease cases. This project will re-sequence samples from the 100,000 Genomes Project, which previously used short-read sequencing. The collaboration aims to demonstrate operational and clinical benefits of long-read sequencing, potentially uncovering additional genomic mutations. Insights from this research may lead to new therapeutic options for patients.